Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
22OCT

EIS tax-relief claimants fell 7%

2 min read
16:30UTC

HMRC counted 33,220 EIS income-tax claimants through Self Assessment in 2024/25, down 7%; investment covered by those claims also fell 7%.

TechnologyDeveloping
Key takeaway

EIS Self Assessment claimants and investment covered by their relief claims both fell 7% in 2024/25.

HM Revenue and Customs (HMRC) published the 2024/25 figures for EIS (the Enterprise Investment Scheme) in May, and the Headline is the people, not the pounds. The number of EIS income-tax claimants through Self Assessment fell 7% to 33,220, down from 35,675⁠1. Investment covered by those relief claims also fell 7%. Separately, provisional company-reported EIS fundraising held at £1,575m across 3,735 companies. HMRC says the series are not directly comparable: investors can carry claims back a year, and some claim through PAYE.

This reporting year pre-dates the April 2026 cut to VCT (Venture Capital Trust) income-tax relief, which fell from 30% to 20% and sat outside this reporting year. The claimant count fell by 2,455, but this does not identify individual angels who stopped investing.

One tier below, SEIS (the Seed Enterprise Investment Scheme) went the other way. Companies raised £276m in 2024/25, up 14%. In the following tax year, 2025/26, advance-assurance requests reached 4,085, up from 3,285⁠2. These request and investment figures cover different tax years; advance assurance does not establish that a company secured funding. London and the South East took 60% of EIS money, down from 63% a year earlier and 65% the year before that, a slow drift of seed capital out of the capital.

Deep Analysis

In plain English

The UK government runs two tax relief programmes to encourage people to invest in small startups. The Enterprise Investment Scheme (EIS) gives investors back 30p for every £1 they put in, via a reduction in their income tax bill. SEIS does the same for even earlier-stage companies, giving back 50p per £1. HMRC's May 2026 release counted 7% fewer EIS income-tax claimants through Self Assessment in 2024/25. Investment covered by those claims also fell 7%. A separate company-reported series put EIS fundraising at £1.575bn, unchanged. Carry-back and PAYE claims prevent a direct comparison, so these figures do not prove that fund managers replaced individual angels. SEIS company fundraising rose 14% to £276m.

Deep Analysis
Root Causes

HMRC counted fewer EIS Self Assessment claimants in 2024/25, but the figures do not establish which investors stopped investing or why. Company-reported funding and investment covered by tax-relief claims measure different series; carry-back and PAYE claims prevent a direct comparison. [HMRC statistics, section 3.6](https://www.gov.uk/government/statistics/enterprise-investment-scheme-and-seed-enterprise-investment-scheme-may-2026/enterprise-investment-scheme-and-seed-enterprise-investment-scheme-2026)

Fund investment does not remove an individual's need to claim relief. HMRC explains that investors using an approved knowledge-intensive fund receive EIS5 from its manager. EIS qualifying holding periods are at least three years. [HMRC investor guidance](https://www.gov.uk/guidance/venture-capital-schemes-tax-relief-for-investors)

What could happen next?
  • Risk

    The April 2026 VCT relief cut will compound the EIS investor-count decline in 2025/26 data, and Wealth Club projects a 65% fall in VCT fundraising to circa £320m, removing a significant channel for Series A follow-on capital.

    Short term · Assessed
  • Opportunity

    The 14% SEIS rise and 24% advance assurance jump indicate founders have internalised SEIS eligibility as a funding design criterion, which should sustain the £276m level even in a quieter angel market.

    Medium term · Suggested
  • Meaning

    London and South East EIS share fell from 63% to 60%, a three-point shift that, if sustained, represents roughly £47m in annual EIS flow redirected toward non-Golden-Triangle companies.

    Short term · Reported
First Reported In

Update #8 · London startup raises Britain's own AI model

HMRC· 14 Jun 2026
Read original →
Different Perspectives
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.
CDP Venture Capital
CDP Venture Capital
CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.
EDBI
EDBI
Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.
Forbion
Forbion
Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.
British Business Bank
British Business Bank
The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.
Stryker Corporation
Stryker Corporation
Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.